Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 5/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | NOS2 | P35228 | 1/20 | 0.33 |
| ▸ | FBP1 | P09467 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19173064 | 0.84 | EPHX1 (0.43) | KMT2AEPHX2SMN1; SMN2EPHX1TSHR | |
| SCHEMBL8958306 | 0.84 | CA2 (0.53) | CA2MEN1KMT2AEPHX2SMN1; SMN2 | |
| SCHEMBL8958443 | 0.84 | CA2 (0.53) | CA2MEN1KMT2AEPHX2SMN1; SMN2 | |
| SCHEMBL8958158 | 0.84 | CA2 (0.53) | CA2MEN1KMT2AEPHX2SMN1; SMN2 | |
| SCHEMBL8958384 | 0.84 | CA2 (0.53) | CA2MEN1KMT2AEPHX2SMN1; SMN2 | |
| SCHEMBL19171981 | 0.83 | MEN1 (0.44) | MEN1KMT2AEPHX2SMN1; SMN2EPHX1 | |
| SCHEMBL6290266 | 0.83 | MEN1 (0.44) | MEN1KMT2AEPHX2SMN1; SMN2EPHX1 | |
| SCHEMBL1415863 | 0.83 | EPHX2 (0.45) | MEN1KMT2AEPHX2SMN1; SMN2EPHX1 | |
| SCHEMBL22526230 | 0.83 | MEN1 (0.44) | MEN1KMT2AEPHX2SMN1; SMN2EPHX1 | |
| SCHEMBL6290192 | 0.83 | CA2 (0.44) | CA2MEN1KMT2AEPHX2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170210736-A1 | PHENYL TETRAHYDROISOQUINOLINE COMPOUND SUBSTITUTED WITH HETEROARYL | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2017-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170210736-A1 | PHENYL TETRAHYDROISOQUINOLINE COMPOUND SUBSTITUTED WITH HETEROARYL | NHERF1, SLC9A3, SLC26A3 | CA2 123/4885MEN1 2007/4885KMT2A 1917/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.